Citadel Advisors
ANIX icon

Citadel Advisors’s Anixa Biosciences ANIX Stock Holding History

Citadel Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.2K Buy
+21,000
New +$62.2K ﹤0.01% 12373
2025
Q3 		– Sell
-14,100
Closed -$46.5K – 12689
2025
Q2 		$46.5K Sell
14,100
-10,400
-42% -$29.7K ﹤0.01% 11805
2025
Q1 		$70.1K Buy
24,500
+17,400
+245% +$49.8K ﹤0.01% 11911
2024
Q4 		$16.5K Sell
7,100
-13,900
-66% -$43.2K ﹤0.01% 13303
2024
Q3 		$66.2K Buy
+21,000
New +$64.6K ﹤0.01% 11619
2024
Q2 		– Sell
-14,500
Closed -$45.2K – 14175
2024
Q1 		$45.2K Buy
14,500
+5,600
+63% +$22.3K ﹤0.01% 12257
2023
Q4 		$34.5K Sell
8,900
-10,200
-53% -$34.4K ﹤0.01% 12142
2023
Q3 		$62.5K Buy
19,100
+6,100
+47% +$21.3K ﹤0.01% 11473
2023
Q2 		$41.6K Buy
13,000
+5,400
+71% +$20.8K ﹤0.01% 12028
2023
Q1 		$32.7K Sell
7,600
-300
-4% -$1.31K ﹤0.01% 12647
2022
Q4 		$33.6K Buy
+7,900
New +$38K ﹤0.01% 12610
2022
Q3 		– Sell
-33,500
Closed -$103K – 12536
2022
Q2 		$103K Buy
+33,500
New +$106K ﹤0.01% 11383
2022
Q1 		– Sell
-17,100
Closed -$51K – 13500
2021
Q4 		$51K Sell
17,100
-15,400
-47% -$62.3K ﹤0.01% 13236
2021
Q3 		$155K Buy
32,500
+22,400
+222% +$101K ﹤0.01% 12338
2021
Q2 		$39K Buy
+10,100
New +$43K ﹤0.01% 13421

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's ANIX Position: Q1 2026 in Review

Citadel Advisors sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 29,692 shares — an estimated $87.9K sold.

Citadel Advisors first reported a position in ANIX in Q4 2020 and held it in 17 quarters. The position peaked at $317K in Q3 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Citadel Advisors reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 29,692 Anixa Biosciences shares in Q1 2026, an estimated $87.9K.
  • Citadel Advisors first reported a position in Anixa Biosciences in Q4 2020 and held it in 17 quarters.
  • Citadel Advisors's Anixa Biosciences position peaked at $317K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.